COVID-19 Response

RedHill is committed to leveraging its research capabilities and proprietary assets to address the global health pandemic caused by the novel coronavirus (COVID-19). RedHill is working closely with regulatory authorities and the scientific community worldwide to evaluate the potential of its two investigational new drugs to treat COVID-19 patients and support the global response to the pandemic.

Learn more about our development programs:

Opaganib - an orally-administered, sphingosine kinase-2 (SK2) selective inhibitor
RHB-107 (upamostat, WX-671) - an orally-administered serine protease inhibitor

To find out more about access to RedHill Biopharma's investigational products, please visit: